Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2019 2
2020 2
2021 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L, Simon S, Vignard V, Dupre E, Gantier M, Cruard J, Alberge JB, Hussong M, Deleine C, Heslan JM, Shaffer J, Beauvais T, Gaschet J, Scotet E, Fradin D, Jarry A, Nguyen T, Labarriere N. Marotte L, et al. Among authors: deleine c. J Immunother Cancer. 2020 Jan;8(1):e000311. doi: 10.1136/jitc-2019-000311. J Immunother Cancer. 2020. PMID: 32001504 Free PMC article.
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer.
Ducoin K, Oger R, Bilonda Mutala L, Deleine C, Jouand N, Desfrançois J, Podevin J, Duchalais E, Cruard J, Benlalam H, Labarrière N, Bossard C, Jarry A, Gervois-Segain N. Ducoin K, et al. Among authors: deleine c. Oncoimmunology. 2022 Mar 9;11(1):2046931. doi: 10.1080/2162402X.2022.2046931. eCollection 2022. Oncoimmunology. 2022. PMID: 35295095 Free PMC article.
Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.
Marotte L, Capitao M, Deleine C, Beauvais T, Cadiou G, Perrin J, Chérel M, Scotet E, Guilloux Y, Bruchertseifer F, Morgenstern A, Jarry A, Gaschet J, Labarriere N. Marotte L, et al. Among authors: deleine c. Oncoimmunology. 2021 Jun 27;10(1):1940676. doi: 10.1080/2162402X.2021.1940676. eCollection 2021. Oncoimmunology. 2021. PMID: 34239774 Free PMC article.
The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer.
Mutala LB, Deleine C, Karakachoff M, Dansette D, Ducoin K, Oger R, Rousseau O, Podevin J, Duchalais E, Fourquier P, Thomas WEA, Gourraud PA, Bennouna J, Brochier C, Gervois N, Bossard C, Jarry A. Mutala LB, et al. Among authors: deleine c. Cancers (Basel). 2021 Jan 7;13(2):189. doi: 10.3390/cancers13020189. Cancers (Basel). 2021. PMID: 33430344 Free PMC article.
The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression.
Eugène J, Jouand N, Ducoin K, Dansette D, Oger R, Deleine C, Leveque E, Meurette G, Podevin J, Matysiak T, Bennouna J, Bezieau S, Volteau C, Thomas WEA, Chetritt J, Kerdraon O, Fourquier P, Thibaudeau E, Dumont F, Mosnier JF, Toquet C, Jarry A, Gervois N, Bossard C. Eugène J, et al. Among authors: deleine c. Mod Pathol. 2020 Mar;33(3):468-482. doi: 10.1038/s41379-019-0322-9. Epub 2019 Aug 13. Mod Pathol. 2020. PMID: 31409873 Free article.
The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer.
Barret JM, Nicolas A, Jarry A, Dubreuil O, Meseure D, Passat T, Perrial E, Deleine C, Champenois G, Gaillard S, Duchalais E, Ray-Coquard I, Lahmar M, Dumontet C, Bennouna J, Bossard C, Roman-Roman S, Prost JF. Barret JM, et al. Among authors: deleine c. Biology (Basel). 2021 Apr 7;10(4):305. doi: 10.3390/biology10040305. Biology (Basel). 2021. PMID: 33917111 Free PMC article.
The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status.
Ott E, Bilonda L, Dansette D, Deleine C, Duchalais E, Podevin J, Volteau C, Bennouna J, Touchefeu Y, Fourquier P, El Alami Thomas W, Chetritt J, Bezieau S, Denis M, Toquet C, Mosnier JF, Jarry A, Bossard C. Ott E, et al. Among authors: deleine c. Oncoimmunology. 2019 Jan 19;8(4):e1562834. doi: 10.1080/2162402X.2018.1562834. eCollection 2019. Oncoimmunology. 2019. PMID: 30906656 Free PMC article.